Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure
Pyridostigmine bromide administered over 8 weeks was associated with a significant reduction of RBC acetylcholinesterase activity and relatively mild symptoms of cholinergic excess, but changes in parasympathetic signaling in the sinoatrial node previously reported after acute administration were not observed. Further investigations are needed to delineate pharmacodynamic and pathobiological factors contributing to these findings. ClinicalTrials.gov identifier: NCT01415921.
Authors
- Manushree Bharadwaj (ORCID: https://orcid.org/0000-0001-8014-8520)
- Alex Reyentovich (ORCID: https://orcid.org/0000-0002-1687-6053)
- Roberta M. Goldring (ORCID: https://orcid.org/0000-0003-3319-4932)
- Carey Pope (ORCID: https://orcid.org/0000-0001-9936-3589)
- David S. Goldstein (ORCID: https://orcid.org/0000-0002-5709-9940)
- Lara K. Maxwell (ORCID: https://orcid.org/0000-0002-0428-0391)
- Stuart D. Katz (ORCID: https://orcid.org/0000-0003-2340-2021)
- Lucy Norcliffe‐Kaufmann (ORCID: https://orcid.org/0000-0003-0702-1333)
- Kenneth I. Berger (ORCID: https://orcid.org/0000-0003-4879-6071)
- Horacio Kaufmann (ORCID: https://orcid.org/0000-0002-1851-9981)
- Randal Goldberg (ORCID: https://orcid.org/0000-0001-8173-3414)
- Judy Zhong (ORCID: https://orcid.org/0000-0002-2163-8447)
- Yu Guo (ORCID: https://orcid.org/0000-0002-6802-0708)
- Ikoa Jeschke-Lopez
Institutions
- Oklahoma State University (US)
- National Institutes of Health (US)
- National Institute of Neurological Disorders and Stroke (US)
- New York University (US)
Publication Details
- Journal
- Current Therapeutic Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.curtheres.2025.100814
- Primary Topic
- Cholinesterase and Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00